Article: PDF OnlyA phase II study of bisantrene in advanced refractory breast cancer An Eastern Cooperative Oncology Group pilot studyPandya, Kishan J., M.D.; Muggia, Franco M., M.D.; Skeel, Roland T., M.D.; Falkson, Geoffrey, M.D.; Kaplan, Barry M., M.D.; Ettinger, David S., M.D.Author Information University of Rochester Cancer Center, Rochester, New York. New York University Medical Center, New York, New York. Medical College of Ohio, Toledo, Ohio. University of Pretoria, Pretoria, South Africa. Albert Einstein College of Medicine, Bronx, New York. Johns Hopkins Oncology Center, Baltimore, Maryland. American Journal of Clinical Oncology: October 1985 - Volume 8 - Issue 5 - p 353–357 Buy Abstract THIRTY PATIENTS WITH ADVANCED REFRACTORY BREAST CANCER received bisantrene 260 mg/m2 intravenously every 3 weeks. Reversible myelosuppression was the most commonly observed side effect. Four patients (13.3%) achieved objective partial response (90% confidence intervals 3–24%), while two patients (6.6%) had disease improvement with a PR + IMP rate of 19.9%. Seven additional patients (23.3%) had stabilization of disease. This drug has antitumor activity against breast cancer and warrants further study, particularly if problems with drug delivery are overcome. © Lippincott-Raven Publishers.